vs
Side-by-side financial comparison of TRICO BANCSHARES (TCBK) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
TRICO BANCSHARES is the larger business by last-quarter revenue ($109.4M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). TRICO BANCSHARES runs the higher net margin — 251.6% vs -49.0%, a 300.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 9.0%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $-84.7M).
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
TCBK vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $109.4M | $70.6M |
| Net Profit | $33.6M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 42.6% | -56.7% |
| Net Margin | 251.6% | -49.0% |
| Revenue YoY | 9.0% | 81958.1% |
| Net Profit YoY | 15.8% | 54.9% |
| EPS (diluted) | $1.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $109.4M | — | ||
| Q3 25 | $107.6M | $70.6M | ||
| Q2 25 | $103.6M | — | ||
| Q1 25 | $98.6M | — | ||
| Q4 24 | $100.4M | — | ||
| Q3 24 | $99.1M | — | ||
| Q2 24 | $97.9M | — | ||
| Q1 24 | $98.5M | — |
| Q4 25 | $33.6M | — | ||
| Q3 25 | $34.0M | $-34.6M | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $26.4M | — | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $29.1M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $27.7M | — |
| Q4 25 | 42.6% | — | ||
| Q3 25 | 43.2% | -56.7% | ||
| Q2 25 | 36.5% | — | ||
| Q1 25 | 35.8% | — | ||
| Q4 24 | 38.7% | — | ||
| Q3 24 | 39.8% | — | ||
| Q2 24 | 40.0% | — | ||
| Q1 24 | 38.3% | — |
| Q4 25 | 251.6% | — | ||
| Q3 25 | 31.6% | -49.0% | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 221.4% | — | ||
| Q3 24 | 29.3% | — | ||
| Q2 24 | 29.7% | — | ||
| Q1 24 | 28.2% | — |
| Q4 25 | $1.02 | — | ||
| Q3 25 | $1.04 | — | ||
| Q2 25 | $0.84 | — | ||
| Q1 25 | $0.80 | — | ||
| Q4 24 | $0.88 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.87 | — | ||
| Q1 24 | $0.83 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $157.0M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $503.0M |
| Total Assets | $9.8B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $157.0M | — | ||
| Q3 25 | $298.8M | $490.9M | ||
| Q2 25 | $314.3M | — | ||
| Q1 25 | $308.3M | — | ||
| Q4 24 | $145.0M | — | ||
| Q3 24 | $320.1M | — | ||
| Q2 24 | $206.6M | — | ||
| Q1 24 | $82.8M | — |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $503.0M | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.9B | $577.1M | ||
| Q2 25 | $9.9B | — | ||
| Q1 25 | $9.8B | — | ||
| Q4 24 | $9.7B | — | ||
| Q3 24 | $9.8B | — | ||
| Q2 24 | $9.7B | — | ||
| Q1 24 | $9.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $133.3M | $-84.6M |
| Free Cash FlowOCF − Capex | $127.9M | $-84.7M |
| FCF MarginFCF / Revenue | 116.9% | -120.1% |
| Capex IntensityCapex / Revenue | 4.9% | 0.2% |
| Cash ConversionOCF / Net Profit | 3.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $222.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $133.3M | — | ||
| Q3 25 | $45.1M | $-84.6M | ||
| Q2 25 | $29.2M | — | ||
| Q1 25 | $24.5M | — | ||
| Q4 24 | $109.7M | — | ||
| Q3 24 | $28.6M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $25.1M | — |
| Q4 25 | $127.9M | — | ||
| Q3 25 | $43.2M | $-84.7M | ||
| Q2 25 | $28.2M | — | ||
| Q1 25 | $22.8M | — | ||
| Q4 24 | $105.2M | — | ||
| Q3 24 | $27.3M | — | ||
| Q2 24 | $30.8M | — | ||
| Q1 24 | $24.1M | — |
| Q4 25 | 116.9% | — | ||
| Q3 25 | 40.2% | -120.1% | ||
| Q2 25 | 27.2% | — | ||
| Q1 25 | 23.1% | — | ||
| Q4 24 | 104.8% | — | ||
| Q3 24 | 27.6% | — | ||
| Q2 24 | 31.5% | — | ||
| Q1 24 | 24.4% | — |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 1.7% | 0.2% | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 3.96× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 0.93× | — | ||
| Q4 24 | 3.78× | — | ||
| Q3 24 | 0.98× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
